Efalizumab

DB00095ApprovedWithdrawnProtein Based TherapiesCD11a-directed Humanized IgG1 Antibody

Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a.

Protein structure of Efalizumab
Mechanism
Curator reviewed
Primary indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.Curator reviewed · 2 structured indications
First approval
Canada, 2005
Also known as
anti-CD11a · antiCD11 alpha
Code names
HU-1124

Resolves to

Compound
UNIIXX2MN88N5DCAS214745-43-4ChEMBLCHEMBL1201575
Clinical / RWD
RxNorm356988ATCL04AG02PharmGKBPA164748817
Targets
P20702ITGAXP20701ITGAL

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
686Drug interactionsStructured to mechanism, not free text
Sign in
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
5Marketed productsAcross 3 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Efalizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In